Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
14.97
-1.98 (-11.68%)
Jan 29, 2026, 4:00 PM EST - Market closed
Palatin Technologies Revenue
Revenue (ttm)
$8.85M
Revenue Growth
+271.10%
P/S Ratio
3.07
Revenue / Employee
$305,088
Employees
29
Market Cap
27.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | 4.49M | -363.59K | -7.49% |
| Jun 30, 2023 | 4.85M | 3.39M | 230.53% |
| Jun 30, 2022 | 1.47M | 1.66M | - |
| Jun 30, 2021 | -188.60K | -306.59K | - |
| Jun 30, 2020 | 117.99K | -60.18M | -99.80% |
| Jun 30, 2019 | 60.30M | -6.83M | -10.18% |
| Jun 30, 2018 | 67.13M | 22.41M | 50.11% |
| Jun 30, 2017 | 44.72M | - | - |
| Jun 30, 2016 | - | - | - |
| Jun 30, 2015 | 12.95M | - | - |
| Jun 30, 2014 | - | - | - |
| Jun 30, 2013 | 10.36K | -63.38K | -85.95% |
| Jun 30, 2012 | 73.74K | -1.40M | -95.00% |
| Jun 30, 2011 | 1.48M | -12.71M | -89.60% |
| Jun 30, 2010 | 14.18M | 2.83M | 24.92% |
| Jun 30, 2009 | 11.35M | -131.51K | -1.15% |
| Jun 30, 2008 | 11.48M | -2.92M | -20.29% |
| Jun 30, 2007 | 14.41M | -5.34M | -27.05% |
| Jun 30, 2006 | 19.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IGC Pharma | 1.11M |
| Rallybio | 674.00K |
| Exicure | 500.00K |
| Serina Therapeutics | 116.00K |
| Daré Bioscience | -57.13K |
PTN News
- 2 months ago - Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option - PRNewsWire
- 3 months ago - Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity - PRNewsWire
- 3 months ago - Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering - PRNewsWire
- 4 months ago - Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim - PRNewsWire
- 5 months ago - Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases - GlobeNewsWire
- 6 months ago - Palatin Announces 1-for-50 Reverse Stock Split - PRNewsWire